The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1250 Weight Loss articles
Fitness enthusiasts and longevity experts are raving about Retatrutide, the new triple-agonist weight-loss peptide dubbed 'the ultimate good' by influencers. Outshining GLP-1 drugs like Ozempic, it targets three receptors for superior fat reduction. As phase 3 trials advance toward FDA approval, here's why it's generating massive buzz.
The FDA has approved Foundayo weight loss pill from Eli Lilly on April 1 (ET), introducing a flexible oral GLP-1 option for adults with obesity or weight-related conditions—no food or water restrictions needed. Trial data shows superior weight loss over Rybelsus, averaging 15-20 pounds vs. 8-11 pounds in diabetes patients. This approval sets up a new showdown in the GLP-1 market dominated by injections like Wegovy and Zepbound.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is investigating peptide clinics for making bold health claims about unregulated therapies. Clinics promote peptides like BPC-157 for injury recovery and MOTS-C for energy, despite scant human evidence. This Guardian-revealed probe highlights risks in the booming peptide market.
Peptides are short amino acid chains hailed by influencers for wellness benefits like injury repair and weight loss, but many lack human evidence. From approved drugs like semaglutide in Wegovy to unregulated options like the 'Wolverine stack' of BPC-157 and TB-500, we examine the science, legality, and risks in the UK.
The NHS has expanded free Wegovy access to 1.2 million more people, but a doctor is urging caution over a 'miserable' side effect: constipation. Dr. Suraj Kukadia explains how GLP-1 medications like Wegovy slow digestion, leading to this common issue. Discover the mechanism and tips for those considering these weight loss jabs.
The rise of Ozempic and similar GLP-1 medications is dramatically altering dining out habits across America, with users ordering less food and leaving meals uneaten. Restaurants face revenue pressures as customers skip courses and reduce alcohol intake. Forward-thinking spots are introducing smaller portions and tapas-style menus to adapt.
Emerging research is raising questions about GLP-1 weight-loss drugs like Ozempic and Wegovy, showing a potential link to bone loss and fractures in older adults. A major study in the Journal of Clinical Endocrinology & Metabolism found higher fragility fracture risks among seniors on these medications. Experts stress monitoring and preventive steps to balance benefits with bone protection.
Emcure Pharmaceuticals is slashing the price of Poviztra semaglutide injection to ₹3,999 per month starting April 3, 2026, making this weight management therapy more accessible across India. As the first Indian firm offering this second brand of Novo Nordisk's semaglutide, Emcure aims to tackle the nation's obesity epidemic affecting over 600 million adults. Backed by 49 million patient years and 50 clinical trials, Poviztra promises validated support for obesity-linked conditions.
Matthew Gallagher, a 41-year-old LA entrepreneur, turned $20,000 into a nearly $2 billion telehealth empire with AI alone. Medvi sells GLP-1 drugs like Ozempic at $300 versus $1,000 retail, serving 250,000 customers. But rapid growth sparks debates on legality and fake ads.
